Hut 8 Corp vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Hut 8 Corp trades at $69.84 (market cap $9.23B), while Ionis Pharmaceuticals Inc. Common Stock trades at $44.03 (market cap $7.10B). The key difference: Hut 8 Corp is the larger of the two by market cap, and Hut 8 Corp is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| HUT | IONS | |
|---|---|---|
Market Cap | $9.23B | $7.10B |
Volume | 12,843,584 | 2,027,457 |
Sector | Financials | Health |
52-Week High | $133.02 | $86.50 |
52-Week Low | $33.76 | $42.38 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $16.67B | $6.66B |
Signals from Pluang's Aura AI — not financial advice
HUT trades at $69.10, down 17.35% in the last 24 hours, with technical indicators showing bearish momentum. The company reported negative earnings in recent quarters, missing expectations, with Q3 2026 results pending. Despite this, analyst sentiment remains overwhelmingly positive with 94% buy ratings and a consensus price target of $163.62. Recent news highlights a $1.07 billion credit facility and significant AI infrastructure contracts, positioning HUT in the growing data center market.
The outlook for HUT is mixed; strong analyst support and expansion in AI infrastructure offer growth potential, but persistent negative earnings and cash flow challenges pose significant risks. Investors should weigh the high valuation multiples against the company's current profitability issues and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →